The Oncology Institute (STLN) is trading down at $6.30 (-0.79%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $187.5M | $203.0M | $252.5M | $324.2M | $393.4M | $502.7M |
| Growth (year over year) | — | +8.3% | +24.4% | +28.4% | +21.3% | +27.8% |
| Operating income | −$8.20M | −$45.9M | −$82.0M | −$77.0M | −$60.1M | −$36.1M |
| Operating margin | −4.4% | −22.6% | −32.5% | −23.8% | −15.3% | −7.2% |
| Net income | −$14.3M | −$10.9M | $152.0K | −$83.1M | −$64.7M | −$60.6M |
| Net margin | −7.6% | −5.4% | 0.1% | −25.6% | −16.4% | −12.1% |
| EPS (diluted) | −$0.24 | −$0.16 | −$0.21 | −$0.92 | −$0.71 | −$0.54 |
| Balance sheet | ||||||
| Cash and equivalents | $900.0K | $115.2M | $14.0M | $33.5M | $49.7M | $33.6M |
| Total assets | $65.7M | $203.4M | $261.7M | $209.2M | $172.7M | $164.7M |
| Total liabilities | $37.6M | $99.3M | $138.5M | $152.2M | $169.1M | $180.4M |
| Long-term debt | $6.56M | $0 | $80.6M | $86.8M | $93.1M | $77.4M |
| Shareholders' equity | $28.1M | $104.2M | $123.2M | $57.0M | $3.59M | −$15.7M |
| Cash flow | ||||||
| Operating cash flow | $508.0K | −$32.7M | −$61.8M | −$36.3M | −$26.5M | −$24.6M |
| Capital expenditure | $1.19M | $2.85M | $5.53M | $4.57M | $3.79M | $3.20M |
| Free cash flow | −$686.0K | −$35.5M | −$67.3M | −$40.9M | −$30.3M | −$27.8M |
| Share buybacks | — | $0 | $9.00M | $1.02M | $0 | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $99.9M | $100.3M | $104.4M | $119.8M | $136.6M | $142.0M | $147.4M | $161.3M |
| Growth (year over year) | +21.8% | +16.9% | +10.3% | +21.5% | +36.7% | +41.6% | +41.2% | +34.6% |
| Operating income | −$13.9M | −$11.9M | −$9.91M | −$11.2M | −$8.05M | −$6.91M | −$6.51M | −$4.62M |
| Operating margin | −13.9% | −11.9% | −9.5% | −9.4% | −5.9% | −4.9% | −4.4% | −2.9% |
| Net income | −$16.1M | −$13.2M | −$19.6M | −$17.0M | −$16.5M | −$7.51M | −$2.49M | −$9.79M |
| Net margin | −16.1% | −13.1% | −18.8% | −14.2% | −12.1% | −5.3% | −1.7% | −6.1% |
| EPS (diluted) | −$0.18 | −$0.14 | −$0.21 | −$0.15 | −$0.14 | −$0.04 | −$0.02 | −$0.08 |
| Balance sheet | ||||||||
| Cash and equivalents | $47.4M | $49.7M | $39.7M | $30.3M | $27.7M | $33.6M | $30.3M | $41.1M |
| Total assets | $179.2M | $172.7M | $164.0M | $159.8M | $163.6M | $164.7M | $168.2M | $178.2M |
| Total liabilities | $163.7M | $169.1M | $158.9M | $168.8M | $175.9M | $180.4M | $184.5M | $203.1M |
| Long-term debt | $91.5M | $93.1M | $73.9M | $75.0M | $76.2M | $77.4M | $78.6M | $79.9M |
| Shareholders' equity | $15.5M | $3.59M | $5.07M | −$8.98M | −$12.3M | −$15.7M | −$16.3M | −$24.9M |
| Cash flow | ||||||||
| Operating cash flow | $819.0K | $4.19M | −$4.99M | −$10.2M | −$12.6M | $3.23M | −$2.21M | $11.9M |
| Capital expenditure | −$402.0K | $1.75M | $328.0K | $1.21M | $604.0K | $1.06M | $1.04M | $908.0K |
| Free cash flow | $1.22M | $2.43M | −$5.32M | −$11.4M | −$13.2M | $2.17M | −$3.26M | $11.0M |
| Share buybacks | $0 | $0 | — | — | — | — | — | — |
From The Oncology Institute's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning The Oncology Institute in our feed yet.